Posted On: 12/29/2015 6:47:43 PM
Post# of 72447
It was certainly a painful day for CMRX shareholders yesterday. Kevetrin used to be the make or break drug for CTIX. But it has been derisked significantly due to the strength of the ABSSSI Phase 2b data. Yes the wait for Phase 3 to start is much longer than expected, but it's definitely worth it since B has become a really really big safety net for shareholders
Quote:
looking at CMRX disaster today, down 80%, makes me even more glad that we have THREE completely different drugs for 4 indications in clinical trials.
(0)
(0)
